Rapid response of facial vitiligo to 308nm excimer laser and topical calcipotriene

Journal of Clinical and Aesthetic Dermatology

Volumn 4, Issue 6, 2011, Pages 41-44

  Mouzakis, John A ^a   Liu, Stephanie ^a   Cohen, George ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIPOTRIOL; STEROID;

ARTICLE; BLISTER; CASE REPORT; CASE STUDY; CHRONIC DISEASE; CLINICAL EVALUATION; DRUG TREATMENT FAILURE; ERYTHEMA; EXCIMER LASER; HUMAN; LOW LEVEL LASER THERAPY; MALE; RADIATION DOSE; SKIN PIGMENTATION; TREATMENT DURATION; TREATMENT OUTCOME; UNITED STATES; VITILIGO;

EID: 80052117747     PISSN: 19412789     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Linthorst Homan MW, Spuls PI, De Korte J, et al. The burden of vitiligo: Patient characteristics associated with quality of life. J Am Acad Dermatol. 2009;61(3):411-420.
2. Ongenae K, Beelaert L, Van Geel N, Naeyaert JM. Psychosocial effects of vitiligo. J Eur Acad Dermatol Venereol. 2006;20(1): 1-8.
3. Kim do Y, Lee JW, Whang SH, et al. Quality of life for Korean patients with vitiligo: Skindex-29 and its correlation with clinical profiles. J Dermatol. 2009;36(6):317-322.
4. Finlay AY, Ryan TJ. Disability and handicap in dermatology. Int J Dermatol. 1996;35:305-311. (Pubitemid 26184699)
5. Kumaran MS, Kaur I, Kumar B. Effect of topical calcipotriol, betamethasone dipropionate and their combination in the treatment of localized vitiligo. J Eur Acad Dermatol Venereol. 2006;20(3):269-273.
6. Sanclemente G, Garcia JJ, Zuleta JJ, et al. A double-blind, randomized trial of 0.05% betamethasone vs. topical catalase/dismutase superoxide in vitiligo. J Eur Acad Dermatol Venereol. 2008;22(11):1359-1364. Epub 2008 Jun 25.
7. Sanclemente G, Garcia JJ, Zuleta JJ, et al. A double-blind, randomized trial of 0.05% betamethasone vs. topical catalase/dismutase superoxide in vitiligo. J Eur Acad Dermatol Venereol. 2008;22(11):1359-1364.
8. Parsad D, Kanwar AJ, Kumar B. Psoralen-ultraviolet A vs. narrow-band ultraviolet B phototherapy for the treatment of vitiligo. J Eur Acad Dermatol Venereol. 2006;20(2):175-177. (Pubitemid 43740518)
9. Bhatnagar A, Kanwar AJ, Parsad D, De D. Comparison of systemic PUVA and NB-UVB in the treatment of vitiligo: an open prospective study. J Eur Acad Dermatol Venereol. 2007;21(5):638-642. (Pubitemid 46916761)
10. Nicolaidou E, Antoniou C, Stratigos A, Katsambas AD. Narrowband ultraviolet B phototherapy and 308-nm excimer laser in the treatment of vitiligo: a review. J Am Acad Dermatol. 2009;60(3):470-477.
11. Falabella R, Barona MI. Update on skin repigmentation therapies in vitiligo. Pigment Cell Melanoma Res. 2009;22(1):42-65.
12. Klahan S, Asawanonda P. Topical tacrolimus may enhance repigmentation with targeted narrowband ultraviolet B to treat vitiligo: a randomized, controlled study. Clin Exp Dermatol. 2009;34(8):e1029-e1030.
13. Kawalek AZ, Spencer JM, Phelps RG. Combined excimer laser and topical tacrolimus for the treatment of vitiligo: A pilot study. Dermatol Surg. 2004;30(2 Pt 1):130-135. (Pubitemid 38313998)
14. Goldinger SM, Dummer R, Schmid P, et al. Combination of 308-nm xenon chloride excimer laser and topical calcipotriol in vitiligo. J Eur Acad Dermatol Venereol. 2007;21(4): 504-508. (Pubitemid 46454904)
15. Cui J, Shen LY, Wang GC. Role of hair follicles in the repigmentation of vitiligo. J Invest Dermatol. 1991;97(3): 410-416.
16. Anbar TS, Westerhof W, Abdel-Rahman AT, El-Khayyat MA. Evaluation of the effects of NB-UVB in both segmental and non-segmental vitiligo affecting different body sites. Photodermatol Photoimmunol Photomed. 2006;22:157-163. (Pubitemid 43805803)
17. Choi KH, Park JH, Ro YS. Treatment of vitiligo with 308-nm xenon-chloride excimer laser: therapeutic efficacy of different initial doses according to treatment areas. J Dermatol. 2004;31:284-292.